Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.50 |
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14989523 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1340804 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL9503018 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| Octane SCHEMBL16440085 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL8345503 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL440982 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1066766 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL2016841 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL1517931 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A | |
| SCHEMBL571427 | 1.00 | FAAH (0.50) | FAAHCES1CES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122079802-A | Cationic lipids and compositions thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | GENZYME CORP (US) | 2026-05-21 | — | — | US | claimed |
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | claimed |
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4712950-A2 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20250381150-A1 | LIPID NANOPARTICLES | GENZYME CORPORATION (US) | 2025-12-18 | — | — | US | claimed |
| EP-4661843-A2 | MULTI-FUNCTIONAL LIPID NANOPARTICLES AND USES THEREOF | University of Tennessee Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4658313-A1 | HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF | GENZYME CORPORATION (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO (US) | 2025-11-20 | — | — | US | claimed |
| US-6645522-B2 | Erythropoietin or derivatives that cause bone marrow cells to increase production of reticulocytes and erythrocytes; hydrogenated lecithin that may be hydrogenated; cholesterol or a derivative; phosphate buffer | CILAG AG (CH) | 2003-11-11 | — | — | US | claimed |
| JP-2002541238-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-20020028236-A1 | ERYTHROPO IETIN LIPOSOMAL DISPERSION | CILAG AG (CH) | 2002-03-07 | — | — | US | claimed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | claimed |
| CN-1298296-A | Erythropoietin Liposomal dispersion | CILAG AG INT (CH) | 2001-06-06 | — | — | CN | claimed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | claimed |
| WO-2000040269-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES | LEE CLARENCE C (US) | 2000-07-13 | — | — | WO | claimed |
| WO-1999042085-A1 | ERYTHROPOIETIN LIPOSOMAL DISPERSION | CILAG AG INTERNATIONAL (CH) | 1999-08-26 | — | — | WO | claimed |
| EP-0937456-A1 | Erythropoietin liposomal dispersion | Cilag AG International (CH) | 1999-08-25 | — | — | EP | claimed |
| US-5856196-A | RESPIRATORY SYSTEM DISORDERS | BETH ISRAEL HOSPITAL (US) | 1999-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381150-A1 | LIPID NANOPARTICLES | CD4, LIPA, PLIN3 | FAAH 1325/4885CES1 1009/4885CES2 2796/4885 |
| US-20250352666-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, EYA3, EYA2 | FAAH 1142/4885CES1 1535/4885CES2 4290/4885 |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | CD2BP2, CD2, CD4 | FAAH 1813/4885CES1 132/4885CES2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.